Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

NCT03164772 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Non-small Cell Lung Cancer
NSCLC

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
BIOLOGICAL: BI 1361849
DEVICE: PharmaJet Tropis® device

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]